Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment [Yahoo! Finance]
Notable Labs, Ltd. - Ordinary Shares (NTBL)
Company Research
Source: Yahoo! Finance
Volasertib Phase 2 trial initiation in relapsed/refractory acute myeloid leukemia anticipated in Q2 2024, and first data in Q4 2024 Relapsed/refractory acute myeloid leukemia constitutes an urgent unmet medical need with typical treatment response rates of 15 percent and a median survival of 6 months or less FOSTER CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced the advancement of its volasertib Phase 2 program utilizing PPMP to enrich the study population for clinical responders. Notable is developing its lead drug asset volasertib with its proprietary PPMP for patients with relapsed/refractory acute myelogenous leukemia (r/r AML). “PPMP's recently reported, 100% accurate prediction of fosciclopirox's clinical trial outcome has allowed us to eliminate
Show less
Read more
Impact Snapshot
Event Time:
NTBL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTBL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTBL alerts
High impacting Notable Labs, Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NTBL
News
- Notable Labs, Ltd. (NASDAQ: NTBL) had its price target lowered by analysts at Chardan Capital from $7.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024GlobeNewswire
- Notable Labs, Ltd. (NASDAQ: NTBL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.MarketBeat
- Notable Labs, Ltd. (NASDAQ: NTBL) had its price target lowered by analysts at Chardan Capital from $9.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Notable Labs Reports 2023 Financial Results and Provides a Business UpdateGlobeNewswire
NTBL
Sec Filings
- 5/15/24 - Form 10-Q
- 5/10/24 - Form 4
- 5/10/24 - Form 4
- NTBL's page on the SEC website